LSD Analogues for Health & Longevity

Evidence Review created on 09/30/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Lysergamides, LSD Analogs, LSD Derivatives, Designer LSD Analogs, 1P-LSD, 1-Propionyl-LSD, ALD-52, 1-Acetyl-LSD, 1cP-LSD, 1B-LSD, 1V-LSD, 1D-LSD, 1T-LSD, ETH-LAD, AL-LAD, PRO-LAD, LSZ, 2-Bromo-LSD, 2-Br-LSD, BOL-148, Bromolysergide, BETR-001, NYPRG-101, Lysergic Acid Amide, LSA, Ergine, DDH-LSD

Motivation

LSD analogues (lysergamides) are close chemical relatives of LSD (lysergic acid diethylamide), the potent mind-altering compound first made in 1938. The family includes designer versions sold online as research chemicals, a natural relative found in morning glory seeds, and newer versions built to avoid hallucinations. Most act either by turning into LSD inside the body or by acting on the same serotonin receptor in the brain.

Interest has grown as modern trials revisited LSD itself for anxiety, low mood and problem drinking, and as legal controls on LSD pushed users toward look-alike compounds that were easier to obtain. People focused on a longer healthy life also ask whether small, repeated doses might offer lasting benefits as they age. At the same time, drug developers are testing versions meant to keep possible benefits without the altered state.

This review examines how LSD analogues work, what human and laboratory evidence exists on their benefits and harms, how they are used and sourced, and how much of their evidence is borrowed from LSD itself, because that distinction shapes how any of it applies to the analogues.

Benefits - Risks - Protocol - Conclusion

This section lists overview-level primary research and expert content on LSD analogues and their shared brain target.

Only four items are listed because no further overview-level content discusses LSD analogues or their shared mechanism in substantial depth; the remaining candidates were brief news items or content focused on other psychedelics.

No LSD analogue content was found from Peter Attia, Rhonda Patrick, Chris Kresser, Life Extension Magazine or Lifespan.io: their sites return no LSD results or only material focused on psilocybin and MDMA (ecstasy, a stimulant with psychedelic-like effects) and brief news items that mention LSD in passing, not the analogues or their mechanism in depth.

Grokipedia

Lysergamides

Overview of the lysergamide class covering LSD’s chemistry, serotonin receptor actions and history, and newer lab-modified analogues such as 1P-LSD, LSZ and ETH-LAD that emerged as novel psychoactive substances.

Examine

No Examine article on LSD analogues exists. Examine covers only the parent compound LSD, not any of its lysergamide analogues.

ConsumerLab

No ConsumerLab article on LSD analogues exists. ConsumerLab tests dietary supplements and does not cover controlled or unregulated psychoactive research chemicals such as lysergamides.

Systematic Reviews

This section lists systematic reviews and meta-analyses relevant to LSD analogues, covering both claimed benefits and principal risks.

Mechanism of Action

LSD, the reference compound, is a partial agonist (an activator producing less than the maximal response) at the 5-HT2A receptor (a serotonin receptor on cortical neurons that drives psychedelic effects), with further activity at other serotonin receptors (5-HT1A, 5-HT2C, and 5-HT2B on heart-valve cells) and dopamine receptors. It also binds TrkB, the receptor for BDNF (brain-derived neurotrophic factor, a neuron growth signal), supporting neuroplasticity, the brain’s capacity to rewire (Moliner et al., 2023).

The analogues fall into three groups:

  • Prodrugs (ALD-52, 1P-LSD, 1cP-LSD, 1B-LSD, 1V-LSD): inactive precursors; a small chemical side-group attached to LSD cuts receptor binding 10- to 100-fold and is removed in the body, releasing LSD (Halberstadt et al., 2020, with a co-author from supplier Synex Synthetics).
  • Direct-acting analogues (ETH-LAD, AL-LAD, LSZ, LSA): activate the receptors themselves, with different potency and duration.
  • Non-hallucinogenic 2-Br-LSD (2-bromo-LSD): a weak 5-HT2A partial agonist that barely recruits β-arrestin (a protein driving receptor shutdown and tolerance) and does not activate 5-HT2B (Lewis et al., 2023).

Two explanations compete: benefit requires the conscious experience, since its intensity tracked anxiety relief (Holze et al., 2023, whose senior authors consult for MindMed), or plasticity alone suffices, the premise behind 2-Br-LSD.

LSD is well absorbed orally, enters the brain readily and has a plasma half-life near 3 hours (Holze et al., 2021); among liver enzymes, CYP2D6 (which breaks down many drugs) most influences its clearance (Vizeli et al., 2021). After oral 1P-LSD, LSD’s half-life was about 6.4 hours (Grumann et al., 2020).

Historical Context & Evolution

Albert Hofmann first synthesized LSD in 1938 at Sandoz while making ergot-derived compounds intended as circulatory and respiratory stimulants. Sandoz chemists then made many relatives: ALD-52, 2-bromo-LSD (BOL-148) and methysergide, a related ergot drug later marketed for migraine prevention and withdrawn from several markets after reports of fibrosis (scar-like tissue growth around organs and heart valves).

In the 1950s, 2-bromo-LSD was studied as a serotonin blocker. Repeated doses reduced volunteers’ later response to LSD (cross-tolerance) (Isbell et al., 1959) and was tested in psychosis, while one report described LSD-like delirium after a small dose (Richards et al., 1958). LSD itself was explored in over a thousand studies for alcoholism and anxiety until scheduling in the late 1960s and 1970s halted most research.

Interest in analogues for health returned by two routes. In 2010, a case series co-authored by John Halpern and Torsten Passie, co-holders of a patent on 2-bromo-LSD for cluster headache, reported relief (Karst et al., 2010), reviving it as a medicine candidate that later attracted companies. From around 2015, 1P-LSD and successors appeared online as uncontrolled alternatives to LSD; as each was banned, a new variant followed.

What changed was evidence rather than consensus: forensic and animal research showed that side-group-modified analogues are converted into LSD, and a two-person human study supported this (Grumann et al., 2020). Modern controlled LSD trials added data on anxiety, while analogue-specific human data remain thin. Both the promise and the harms of the analogues are still being assessed.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no controlled trial has tested any LSD analogue for a clinical outcome, and the replicated trial evidence concerns LSD itself, reaching the analogues only indirectly.

Medium 🟩 🟩

No benefit reaches Medium: the only human analogue data are a two-person pharmacokinetic (drug absorption and clearance) study, an uncontrolled case series and user surveys, none testing a clinical outcome under controlled conditions.

Low 🟩

Reduced anxiety and depressive symptoms

Converting analogues such as 1P-LSD, ALD-52 and 1cP-LSD are expected to share LSD’s effect because they become LSD in the body. The trials tested LSD itself, not any analogue, and conversion rests on a two-person 1P-LSD study, so the evidence is indirect. Trial doses were high and supervised.

Magnitude: In a phase 2b (mid-stage, dose-finding) trial of 198 adults with generalized anxiety disorder (persistent, excessive worry), single 100 µg and 200 µg LSD doses lowered HAM-A (Hamilton Anxiety Rating Scale, a clinician-rated anxiety score) by 5.0 and 6.0 points more than placebo at 4 weeks; the trial was sponsored and largely authored by developer MindMed (Robison et al., 2025). A Basel academic trial, whose senior authors consult for MindMed and whose data were licensed to it, found an anxiety Cohen’s d (a standardized effect size; 0.8 or more counts as large) of −1.18 at 16 weeks (Holze et al., 2023). Oral 1P-LSD delivered close to 100% of its dose as LSD (Grumann et al., 2020).

Reduced problem drinking

A single LSD session within alcohol treatment programmes was linked to less alcohol misuse in 1960s trials. No analogue has been tested, so relevance to analogues depends on their conversion to LSD. Blinding and follow-up in these older trials were uneven.

Magnitude: Pooled OR (odds ratio, how many times more likely the outcome was with LSD) 1.96 with a 95% CI (confidence interval, the range likely to contain the true value) of 1.36–2.84 for improvement in alcohol misuse across six LSD trials with 536 participants (Krebs & Johansen, 2012).

Fewer cluster headache attacks

Cluster headache is a rare, extremely painful one-sided headache recurring in bouts. Non-hallucinogenic 2-Br-LSD was given as three doses in an open-label (unblinded, uncontrolled) case series, and seed-derived LSA was rated preventive by many patients in an online survey. Neither design had a control group.

Magnitude: Across three LSA studies of 120 mostly forum-recruited patients, about 20% reported it effective in preventing attacks (Castro et al., 2025); in a survey of 496 patients run with the patient nonprofit Clusterbusters, whose members derive no revenue from these compounds, LSA was rated comparable to or more effective than most conventional preventive medications (Schindler et al., 2015); the 2-Br-LSD case series reported fewer attacks after three 30 µg/kg doses but gave no controlled effect size (Karst et al., 2010).

Better everyday mood, focus and cognition from microdosing ⚠️ Conflicted

Microdosing means taking about a tenth of a full dose every few days. User surveys report better mood and focus, but controlled LSD trials found little advantage over placebo. No analogue microdosing trial exists. Net: reported benefits are largely explained by expectation rather than the drug.

Magnitude: In 191 self-blinded psilocybin or LSD microdosers, outcomes improved equally in microdose and placebo groups with no significant difference (Szigeti et al., 2021); twice-weekly 20 µg LSD for adult ADHD (attention-deficit/hyperactivity disorder) improved symptom scores by 7.1 points versus 8.9 on placebo (Mueller et al., 2025).

Longer sleep after microdosing

In a placebo-controlled trial, 80 healthy men taking 10 µg LSD every third day slept longer the night after dosing, measured by wearable trackers. Sleep stages and activity were unchanged. The trial used LSD, not an analogue, and included no women.

Magnitude: 24.3 extra minutes of sleep per night (95% CI 10.3–38.3) versus placebo on post-dose nights (Allen et al., 2024).

Higher pain tolerance at low doses

A single 20 µg LSD dose lengthened how long healthy volunteers tolerated ice-cold water and lowered pain ratings without a full psychedelic state. The study tested LSD in 24 people; no analogue or chronic-pain population has been studied.

Magnitude: LSD 20 µg increased cold-water tolerance time by about 20% and reduced pain and unpleasantness ratings versus placebo, while 5 µg and 10 µg had no significant effect (Ramaekers et al., 2021).

Speculative 🟨

Neuron growth and stress resilience without hallucinations

In rat neurons and mice, 2-Br-LSD promoted dendritic spines (connection points between neurons) and reversed chronic-stress behaviour without hallucination-like responses (Lewis et al., 2023). The basis is laboratory and animal work; no human data exist.

Slower ageing through calorie-restriction-like signalling

In roundworms, LSD extended lifespan and reduced age pigment, mimicking calorie restriction through reduced TOR (a nutrient-sensing growth pathway) signalling (Carrilho et al., 2025). The basis is one unreviewed worm preprint; no analogue was tested.

Protection against brain inflammation and dementia

Serotonin 2A activation reduces inflammation in animal models, motivating a low-dose LSD safety trial in older adults by developer Eleusis (Family et al., 2020). No analogue has been studied; the basis is mechanistic.

Benefit-Modifying Factors

  • Genetics (CYP2D6): people with no working CYP2D6 had about 75% higher LSD exposure and stronger, longer effects (Vizeli et al., 2021); for converting analogues the same enzyme clears the released LSD, so a given dose may act more strongly.
  • Baseline symptom scores: no blood biomarker predicts benefit; people with depressed mood felt stronger positive effects from a low LSD dose (Molla et al., 2024), and trial benefits appeared in moderate-to-severe anxiety, not in healthy volunteers.
  • Sex: sex-specific data are sparse; most LSD studies pooled men and women without reporting differences, and the sleep finding came from men only, so it may not transfer to women.
  • Pre-existing conditions: anxiety disorders, alcohol use disorder and cluster headache carry the clearest signals; healthy people and adults with ADHD showed little measurable benefit from microdosing in controlled trials (Szigeti et al., 2021; Mueller et al., 2025).
  • Age: adults averaging 63 years tolerated 5–20 µg LSD every fourth day without cognitive or balance impairment (Family et al., 2020), but benefit in older adults is untested and full-dose trials rarely enrol people over 65.
  • Expectation and setting: expectation strongly shapes microdosing outcomes, and trials showing benefit paired full doses with preparation, supervision and follow-up sessions.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the replicated adverse-event data come from LSD trials, while analogue-specific harms are documented only in case reports, surveys and forensic analyses.

Medium 🟥 🟥

No risk reaches Medium: no analogue has a controlled trial or systematic observational cohort measuring adverse events.

Low 🟥

Acute anxiety, confusion and dangerous behaviour

Full doses can cause panic, confusion and impaired judgement for 8–12 hours. LSD trials show dose-dependent unpleasant effects; a confirmed ETH-LAD case involved aggression, injuries, unconsciousness and 17 days in hospital. Analogue risk is inferred from LSD data plus case reports.

Magnitude: Ratings above 50% on the “bad drug effect” scale occurred in 9%, 27% and 31% of LSD administrations at 50, 100 and 200 µg in pooled trials of 83 healthy volunteers (Holze et al., 2022); ETH-LAD case: (Nadler et al., 2026).

Raised heart rate, blood pressure and body temperature

LSD moderately raises heart rate, blood pressure and temperature. A fatal dysrhythmia (disturbed heart rhythm) was reported after AL-LAD use, though causation from one case is uncertain. Heart disease or stimulant co-use likely raises risk.

Magnitude: Heart rate above 100 beats/min in 20% and 25%, and temperature above 38 °C in 7% and 34%, of LSD administrations at 100 and 200 µg; no systolic pressure exceeded 180 mmHg (Holze et al., 2022); fatal AL-LAD case: (Blumenberg & Hendrickson, 2020).

Nausea and headache

Nausea and headache are the most common physical effects in LSD trials and rise with dose. LSA from seeds causes notably more nausea and vomiting. Both usually resolve within a day.

Magnitude: Nausea in 40% and 60% and headache in 35% and 27.5% of participants after 100 and 200 µg LSD, versus 7.7% and 23.1% on placebo (Robison et al., 2025).

Lingering visual disturbances

Some users report drug-free visual effects resembling the drug state; when persistent and distressing this is called HPPD (hallucinogen persisting perception disorder). Evidence comes from surveys and LSD trials; no analogue-specific data exist.

Magnitude: Of 2455 hallucinogen users surveyed online, 60.6% reported drug-free visual effects but 4.2% found them distressing enough to consider treatment (Baggott et al., 2011); 6 of 83 trial volunteers reported transient flashbacks (Holze et al., 2022).

Persistent psychosis or mania in vulnerable people

Psychedelics can trigger lasting psychosis or mania (abnormally elevated mood and energy), mainly with a personal or family history of psychotic or bipolar disorder. Rates are low in screened trials and higher in unscreened use. The ETH-LAD case developed persistent psychosis (Nadler et al., 2026).

Magnitude: Psychedelic-induced psychosis incidence of 0.002% in population studies, 0.2% in uncontrolled trials and 0.6% in randomized trials, and 3.8% in uncontrolled studies including people with schizophrenia (Sabé et al., 2025).

Worsening depression or suicidal behaviour in psychiatric patients

Serious psychiatric adverse events, including worsening depression and suicidal behaviour, occurred occasionally in trials of LSD and other classic psychedelics in people with existing psychiatric disorders, not in healthy volunteers. Evidence comes from LSD and related trials; no analogue data exist.

Magnitude: Serious adverse events, including worsening depression, suicidal behaviour, psychosis and seizures, affected about 4% of participants with pre-existing neuropsychiatric disorders and no healthy participants across 3504 trial participants (Hinkle et al., 2024).

Blood vessel constriction and high blood pressure with LSA

Seeds containing LSA also carry other ergot alkaloids that constrict blood vessels. Reported harms include high blood pressure, hospitalisation and posterior reversible encephalopathy syndrome (blood-pressure-driven brain swelling with seizures). Evidence comes from case reports and uncontrolled studies.

Magnitude: About 12.3% (27 of 219) of LSA users across the 17 reviewed human studies required medical attention, with no overdoses recorded (Castro et al., 2025); encephalopathy case: (Legriel et al., 2008).

Misidentified or mislabelled products

Analogues are sold as unregulated research chemicals, usually on blotter paper, with no dose or identity guarantee. Forensic chemists found blotters labelled 1D-LSD that contained a different analogue, 1T-LSD. Unknown content means unpredictable potency and duration.

Magnitude: Not quantified in available studies. Only forensic case analyses of seized products exist, without systematic market sampling (Okada et al., 2024).

Psychoactive effects of 2-Br-LSD ⚠️ Conflicted

Mouse data and a cluster headache series without hallucinations support 2-Br-LSD being non-hallucinogenic. A 1958 report described LSD-like delirium after a small dose, and a 2011 commentary questioned the label. Net: at studied doses it appears largely non-hallucinogenic, but individual reactions cannot be excluded.

Magnitude: Not quantified in available studies. Only single case reports, commentary and one small uncontrolled series exist (Richards et al., 1958; Tfelt-Hansen, 2011).

Speculative 🟨

Heart valve damage with frequent microdosing

LSD activates 5-HT2B, the mechanism behind valve disease from fenfluramine and methysergide, so frequent microdosing could add up (Tagen et al., 2023). The basis is mechanistic; no human data exist. 2-Br-LSD lacks this activity.

Unknown toxicity of newer analogues

Newer analogues such as 1V-LSD, 1D-LSD and 1T-LSD lack human safety data. Computer modelling alone flagged possible heart-rhythm toxicity for 1V-LSD (Jurowski et al., 2026); 1D-LSD and 1T-LSD were not included.

Risk-Modifying Factors

  • Genetics (CYP2D6): poor metabolizers have about 75% higher LSD exposure and longer effects (Vizeli et al., 2021), raising the chance of prolonged or overwhelming experiences with converting analogues; CYP2D6-inhibiting drugs mimic this.
  • Family history: a first-degree relative with psychotic or bipolar disorder raises psychosis and mania risk; controlled trials exclude these people.
  • Baseline blood pressure and heart health: resting blood pressure above 140/90 mmHg, arrhythmias or known heart valve disease amplify cardiovascular strain from full doses.
  • Sex: no established sex difference in adverse effects; pregnancy is a separate concern, as no safety data exist and ergot relatives such as LSA may theoretically stimulate uterine contraction.
  • Pre-existing conditions: seizure disorders, severe anxiety or panic disorder, and liver impairment (slower LSD clearance) raise the likelihood or severity of adverse events.
  • Age: older adults tolerated 5–20 µg LSD (Family et al., 2020), but full doses in people over 65 with cardiovascular disease are largely unstudied; impaired balance at higher doses raises fall risk.

Key Interactions & Contraindications

  • Lithium (absolute contraindication): 47% of 62 online reports of lithium plus psychedelics described seizures and 39% needed medical attention (Nayak et al., 2021). No safe spacing is established, so avoidance is the only mitigation.
  • SSRIs and SNRIs (serotonin-boosting antidepressants: sertraline, escitalopram, venlafaxine; caution): usually blunt effects, prompting risky dose escalation. Mitigation: antidepressants are not stopped abruptly to regain effects; any taper happens only under prescriber supervision.
  • Monoamine oxidase inhibitors (older antidepressants that block serotonin breakdown: phenelzine, tranylcypromine; caution): unpredictable interaction with blunted or altered effects and theoretical serotonin toxicity (dangerous serotonin excess causing fever, agitation, rigidity). Mitigation: avoiding the combination.
  • Strong CYP2D6 inhibitors (bupropion, fluoxetine, paroxetine; monitor): likely raise and prolong LSD levels, mimicking poor-metabolizer genetics, with longer, more intense effects. Mitigation: a reduced dose and longer supervision.
  • 5-HT2A blockers and antipsychotics (ketanserin, risperidone, quetiapine; monitor): blunt or reverse effects; ketanserin shortened LSD effects from 8.5 to 3.5 hours (Becker et al., 2023). Mitigation: used deliberately as medical rescue.
  • Triptans and ergot drugs (migraine drugs that narrow blood vessels: sumatriptan, ergotamine, methysergide; caution): additive blood vessel constriction, especially with LSA, risking high blood pressure. Mitigation: avoiding same-day use.
  • Tramadol (caution): lowers seizure threshold and adds serotonin-boosting activity, raising seizure and serotonin toxicity risk. Mitigation: avoiding the combination.
  • Dextromethorphan, over-the-counter cough suppressant (caution): serotonin-boosting and cleared by CYP2D6, risking serotonin toxicity and unpredictable effects. Mitigation: avoiding it on dosing days.
  • Decongestants (pseudoephedrine, phenylephrine; caution): additive blood pressure and heart rate rise. Mitigation: avoiding them on dosing days and checking blood pressure.
  • Serotonin-boosting supplements (St John’s wort, 5-HTP or 5-hydroxytryptophan, L-tryptophan, SAMe or S-adenosylmethionine; caution): additive serotonin-boosting activity with theoretical serotonin toxicity; St John’s wort may also alter drug metabolism. Mitigation: pausing them at least one week before dosing.
  • Stimulating supplements (high-dose caffeine, yohimbine, synephrine; monitor): additive heart rate, blood pressure and anxiety increases. Mitigation: skipping them on dosing days.
  • Other substances (MDMA or ecstasy, amphetamine, cocaine, cannabis, alcohol; caution): stimulants add cardiovascular load; cannabis can intensify anxiety and psychotic symptoms; alcohol worsens judgement. Mitigation: avoiding combinations.

Populations who should avoid LSD Analogues:

  • Personal history of a psychotic disorder or bipolar I disorder, or a first-degree relative with either
  • Resting blood pressure ≥140/90 mmHg despite treatment, heart attack or stroke within the past 6 months, significant arrhythmia, or known heart valve disease
  • Pregnancy or breastfeeding
  • Current lithium treatment
  • Epilepsy or any history of unprovoked seizures
  • Adolescents under 18 years
  • Severe liver impairment (Child-Pugh Class C, the most advanced category of liver dysfunction)

Risk Mitigation Strategies

  • Screening before any use: a review of personal and family psychiatric history, medications and cardiovascular status mitigates psychosis, mania and cardiac events, the harms most tied to unscreened use.
  • Supervised, safe setting: a sober, experienced monitor and a familiar, hazard-free space for the full 8–12 hours mitigate panic, confusion and accidental injury.
  • Identity testing: laboratory drug-checking or reagent kits before use mitigate the risk of mislabelled analogues with unexpected potency or duration.
  • Fractional first dose: starting at one quarter of the intended dose and waiting at least 2–3 hours before any more mitigates overdose from the delayed onset of converting analogues.
  • Blood pressure check: measurement before dosing and at 2–3 hours, with use deferred at resting pressure ≥140/90 mmHg, mitigates cardiovascular strain.
  • Limited microdosing courses: courses capped at 4–8 weeks with equal breaks, plus an echocardiogram (heart ultrasound) after prolonged use, mitigate the theoretical heart valve risk.
  • Interaction avoidance: no lithium, tramadol, stimulants or serotonin-boosting supplements on dosing days mitigates seizures, serotonin toxicity and cardiovascular overload.
  • No driving for 48 hours: Basel trials require 48 hours without operating heavy machinery (NCT07309471); this mitigates accidents from lingering impairment.
  • Rescue plan: access to a clinician who can give a benzodiazepine (a fast-acting sedative) or ketanserin for severe, unremitting distress mitigates prolonged panic or dangerous agitation.

Therapeutic Protocol

  • Reference regimen (LSD trials): one or two supervised 100–200 µg LSD sessions with preparation and follow-up, as used by Matthias Liechti’s Basel group and MindMed’s MM120 programme; no analogue has a trial-tested regimen.
  • 1P-LSD dose equivalence: 100 µg of 1P-LSD in its usual salt form contains about 70 µg LSD by molecular weight; with near-complete conversion, users treat it as roughly equipotent to LSD.
  • Microdosing schedule: James Fadiman popularized 10–20 µg every third day for 4–10 weeks; controlled LSD trials used 5–26 µg every 3–4 days.
  • 2-Br-LSD for cluster headache: three oral doses of 30 µg/kg spaced several days apart, from the Karst et al., 2010 case series, whose co-author Halpern co-holds a patent on this use; not a validated regimen.
  • Competing approaches: supervised high-dose sessions, sub-perceptual microdosing and non-hallucinogenic analogues rest on different mechanisms and evidence; none is established as the default.
  • Time of day: morning dosing lets 8–12 hours of effects end before bedtime; microdoses are also taken in the morning to limit sleep disruption.
  • Half-life: LSD has a plasma half-life near 3 hours; after oral 1P-LSD it was about 6.4 hours in one study (Grumann et al., 2020). Effects last well beyond measurable levels.
  • Single versus split dosing: single doses are standard; redosing, often prompted by delayed onset of converting analogues, prolongs effects and deepens tolerance.
  • Genetics: CYP2D6 poor metabolizers, or people taking CYP2D6 inhibitors, may need lower doses; CYP2D6 genotyping is commercially available.
  • Sex: no sex-specific dosing exists; body-weight dosing appears only for 2-Br-LSD. A trial of LSD microdosing for premenstrual disorders is pending.
  • Age: older adults tolerated 5–20 µg LSD (Family et al., 2020); full doses above 65 are largely unstudied, favouring the lowest effective dose.
  • Baseline biomarkers: trial protocols exclude people with blood pressure above 140/90 mmHg (NCT07309471); baseline symptom scores guide expected response.
  • Pre-existing conditions: anxiety trials used 100–200 µg with therapy; adult ADHD showed no microdosing benefit (Mueller et al., 2025); cluster headache approaches remain investigational.

Discontinuation & Cycling

  • Episodic, not lifelong: use is short-term, either one or two full-dose sessions or time-limited microdosing courses; no regimen is designed for continuous lifelong use.
  • Withdrawal: no physical dependence or withdrawal syndrome is known; some people report low mood or fatigue for a day after full doses.
  • Tapering: not required; converting analogues and LSD can be stopped at any time without dose reduction.
  • Tolerance and cycling: tolerance builds within days and crosses over between LSD and analogues such as 2-bromo-LSD (Isbell et al., 1959); spacing full doses at least two weeks apart and pausing microdosing every 4–8 weeks restores response.

Sourcing and Quality

  • No pharmaceutical-grade analogue: only LSD itself (MM120) is made to GMP (Good Manufacturing Practice, regulated drug-quality standards), and only for trials; every analogue is an unregulated research chemical.
  • Identity testing: laboratory drug-checking services give the most reliable identification; Ehrlich reagent kits detect lysergamides but cannot distinguish individual analogues and may react weakly with converting analogues.
  • Analytical confusion: ALD-52 and 1P-LSD can convert to LSD during common laboratory analysis, so test results may report LSD when the product was an analogue (Zhang et al., 2023).
  • Dose uniformity: doses vary between blotter squares; volumetric dosing from a measured solution in distilled water or alcohol gives more consistent microdoses. Cool, dark and dry storage slows degradation.
  • Supplier reputation: no vendor can be called reputable in a pharmaceutical sense; reference material in key 1P-LSD studies came from Synex Synthetics BV, whose staff co-authored those papers.
  • Legal-status churn: each national ban spawns newer, less-studied variants, so the newest analogue on sale usually has the least safety data.

Practical Considerations

  • Time to effect: acute effects begin within 30–60 minutes, peak at 2–4 hours and last 8–12 hours; anxiety improvements in LSD trials were measured from 4 to 16 weeks after one dose.
  • Common pitfalls: treating “legal” as “tested”, redosing when a converting analogue seems slow, combining with other substances, and expecting microdosing effects that controlled trials did not confirm.
  • Regulatory status: LSD is US Schedule I (the strictest drug category); analogues may be prosecuted under the US Federal Analogue Act, fall under the UK Psychoactive Substances Act 2016 and Germany’s new psychoactive substances law, and have no approved medical use.
  • Cost and access: grey-market analogues are inexpensive but legally risky; supervised LSD therapy is available only in trials or limited compassionate-use programmes, such as Switzerland’s, and is not insurance-covered.
  • Structural funding bias: unpatentable converting analogues attract no trial sponsor, while patentable non-hallucinogenic versions draw investment; costly supervised sessions versus cheap daily generic antidepressants give insurers a short-term incentive favouring generics, biasing research funding and guidelines.

Interaction with Foundational Habits

  • Sleep: direct, dose-dependent. Full doses cause 8–12 hours of wakefulness and can disrupt that night’s sleep, so dosing is done in the morning; LSD microdoses lengthened the next night’s sleep by about 24 minutes (Allen et al., 2024).
  • Nutrition: indirect. No nutrient depletion is known; a light meal a few hours before dosing may ease nausea, particularly with LSA seeds, and steady hydration helps during temperature rises.
  • Exercise: none for microdoses, which left daily physical activity unchanged in a controlled trial (Allen et al., 2024); full doses raise heart rate and temperature, so strenuous training is avoided during the acute 8–12 hours.
  • Stress management: potentiating. Preparation, calm surroundings and practices such as meditation or slow breathing shape the experience and reduce panic; LSD acutely raises stress hormones such as cortisol, so the dosing day is kept free of other stressors.

Monitoring Protocol & Defining Success

Before starting, baseline testing covers resting blood pressure and heart rate, an ECG (electrocardiogram, a heart electrical tracing), liver enzymes, a validated anxiety or depression questionnaire, and a structured review of personal and family psychiatric history; people planning repeated microdosing may add an echocardiogram and CYP2D6 genotype. On each dosing day, blood pressure and heart rate are checked before dosing and at 2–3 hours. Ongoing monitoring follows a set cadence: symptom questionnaires at 1 week, 4 weeks and 12 weeks after a full-dose session, and blood pressure, heart rate and liver enzymes every 3–6 months during repeated use. For microdosing lasting beyond 6 months, an echocardiogram every 12 months screens for valve changes. Success means a sustained, meaningful improvement in symptom scores or quality of life without new adverse findings.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Resting blood pressure <120/80 mmHg Cardiovascular strain Defer dosing at ≥140/90 mmHg; conventional “normal” also <120/80; measure seated after 5 minutes’ rest
Resting heart rate 50–70 beats/min Stimulation, arrhythmia risk Conventional range 60–100; defer dosing if >100
QTc interval on ECG <430 ms (men), <450 ms (women) Heart rhythm safety ECG is electrocardiogram, a heart electrical tracing; QTc is heart-rate-corrected repolarization time; conventional limits <450 ms men and <460 ms women; relevant given a fatal AL-LAD dysrhythmia case
Heart valve echocardiogram No valve leakage or thickening Serotonin 2B valve risk Heart ultrasound; for repeated microdosing beyond 6 months; no established analogue-specific threshold, so compare with own baseline
ALT <25 U/L Liver clearance capacity ALT is alanine aminotransferase, a liver enzyme; conventional upper limit about 40–56 U/L; fasting not required; pair with AST (aspartate aminotransferase)
GAD-7 score <5 Anxiety response GAD-7 is a 7-item generalized anxiety questionnaire; 5–9 mild, ≥10 moderate; track change from own baseline
PHQ-9 score <5 Depression response PHQ-9 is a 9-item depression questionnaire; ≥10 indicates moderate depression; repeat at the same time of day
CYP2D6 genotype Normal metabolizer Predicts exposure and duration One-time test; poor metabolizers have about 75% higher LSD exposure; no functional “range” applies

Qualitative markers of success:

  • Sustained improvement in mood, anxiety and emotional flexibility beyond the acute effects
  • Sleep quality and duration, especially the night after dosing
  • Energy, focus and cognitive clarity in daily tasks
  • Absence of lingering visual disturbances, persistent anxiety or unusual thoughts
  • Changes in alcohol or other substance use
  • Frequency and severity of cluster headache attacks, where relevant

Emerging Research

  • DDH-LSD first-in-human trial: a Basel randomized, placebo-controlled crossover study (each participant receives every treatment in turn) in 24 healthy adults comparing a new shorter-acting lysergamide with LSD for half-life, duration and effects (NCT07309471); could yield the first controlled human data on a non-converting analogue.
  • 2-Br-LSD (BOL-148) for cluster headache: Ceruvia Lifesciences funded an integrated phase 1/2 study, gradually increased single doses in healthy adults then a randomized, placebo-controlled patient phase, with enrolment targeted for late 2026; no NCT ID yet (AllSci report).
  • Phase 3 LSD (MM120, now DT120) trials: Voyage in 214 (NCT06741228) and Panorama in 245 adults (NCT06809595) with generalized anxiety disorder, and Emerge in 149 with major depression (NCT06941844), reported positive, not yet peer-reviewed headline results in 2026 (developer press release).
  • LSD for cluster headache: placebo-controlled phase 2 trials in Nijmegen with 65 chronic patients (NCT05477459) and in Basel with 30 patients (NCT03781128); positive or null results would test survey-based signals.
  • Microdosing for premenstrual disorders: a 150-woman trial comparing daily and alternate-day 10 µg LSD with placebo (NCT07189299); one of few microdosing trials designed around women.
  • Longevity signal: LSD extended roundworm lifespan with calorie-restriction-like changes in an unreviewed preprint (Carrilho et al., 2025); replication in mammals would be needed before any longevity claim.
  • Controlled analogue data in animals: a randomized, blinded trial of 10 µg 1cP-LSD in 20 shelter dogs reported calmer behaviour when combined with behavioural therapy (Hernández-Álvarez et al., 2026).
  • Evidence that could weaken the case: heart valve risk from repeated 5-HT2B activation (Tagen et al., 2023) and expectation effects explaining microdosing benefits (Szigeti et al., 2021); larger 1P-LSD conversion studies could also reveal differences from LSD.

Conclusion

LSD analogues are a mixed family: designer compounds that the body turns into LSD, relatives that act on the brain directly, a natural compound found in seeds, and newer versions built to avoid hallucinations. For health-focused adults, their appeal rests mostly on trial evidence for LSD itself, especially lasting anxiety relief after supervised sessions and possible help with problem drinking.

That evidence reaches the analogues only indirectly. Human data on the analogues themselves come from a tiny dosing study, surveys and case reports, so every benefit is graded low or speculative. Small, repeated doses have not clearly outperformed placebo in careful studies, and hopes for slower ageing rest on worm and animal work.

The main risks are frightening or disorienting experiences, strain on the heart and circulation, rare lasting loss of touch with reality in vulnerable people, dangerous reactions with lithium, and products that are not what their labels say. Frequent small doses carry an unmeasured possibility of heart valve harm.

The evidence carries interests on several sides. Much of the modern LSD trial data comes from companies developing LSD medicines or from academic groups tied to them, the key laboratory and headache work on the non-hallucinogenic version involves its developer and patent holders, and early human data on the most common designer analogue involved staff of a supplier selling it. Patient-group surveys whose organisers have no sales interest add uncontrolled signals. The analogues remain an experimental, largely unregulated extension of a promising but still maturing parent compound.

Top - Benefits - Risks - Protocol